Laboratory Corp. of America (NYSE:LH) is scheduled to be releasing its earnings data before the market opens on Thursday, October 24th. Analysts expect Laboratory Corp. of America to post earnings of $2.85 per share for the quarter. Laboratory Corp. of America has set its FY19 guidance at $11.10-$11.40 EPS and its FY 2019 guidance at $11.10-11.40 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.
Laboratory Corp. of America (NYSE:LH) last issued its quarterly earnings data on Thursday, July 25th. The medical research company reported $2.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.90 by $0.03. The firm had revenue of $2.88 billion during the quarter, compared to analysts’ expectations of $2.89 billion. Laboratory Corp. of America had a net margin of 8.19% and a return on equity of 16.28%. The business’s revenue was up .5% on a year-over-year basis. During the same period last year, the company earned $2.98 earnings per share. On average, analysts expect Laboratory Corp. of America to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.
Shares of NYSE LH opened at $167.62 on Wednesday. The stock has a market capitalization of $16.43 billion, a P/E ratio of 15.21, a P/E/G ratio of 1.87 and a beta of 1.03. The company has a 50-day moving average price of $168.98 and a 200-day moving average price of $166.33. Laboratory Corp. of America has a 1 year low of $119.38 and a 1 year high of $178.44. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.14 and a quick ratio of 1.05.
A number of brokerages have recently issued reports on LH. Bank of America upgraded shares of Laboratory Corp. of America from an “underperform” rating to a “neutral” rating and set a $174.60 price objective for the company in a report on Tuesday, July 16th. Zacks Investment Research upgraded shares of Laboratory Corp. of America from a “sell” rating to a “hold” rating and set a $172.00 price objective for the company in a report on Wednesday, October 9th. UBS Group reduced their price objective on shares of Laboratory Corp. of America from $204.00 to $200.00 and set a “buy” rating for the company in a report on Monday. Barclays set a $200.00 price objective on shares of Laboratory Corp. of America and gave the company a “buy” rating in a report on Monday, July 15th. Finally, KeyCorp lifted their price objective on shares of Laboratory Corp. of America from $172.00 to $192.00 and gave the company an “overweight” rating in a report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $184.91.
In related news, SVP Lance Berberian sold 5,902 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $169.80, for a total transaction of $1,002,159.60. Following the transaction, the senior vice president now directly owns 6,097 shares of the company’s stock, valued at $1,035,270.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kerrii B. Anderson sold 2,600 shares of the firm’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $171.85, for a total transaction of $446,810.00. The disclosure for this sale can be found here. Insiders have sold 11,468 shares of company stock worth $1,946,168 over the last three months. 0.74% of the stock is owned by insiders.
Laboratory Corp. of America Company Profile
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
See Also: Quick Ratio
Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.